SHH (sonic hedgehog signaling molecule; HGNC:10848, NCBI Gene 6469) is the gene on chromosome 7q36.3 encoding the SHH morphogen — the doubly lipidated signal of the Hedgehog pathway whose concentration gradients pattern the neural tube, limb bud, and left-right axis; the gene whose London-based naming (after the video-game character) became nomenclature folklore; the protein page holds the signaling anatomy.
Approved Symbol
SHH (HGNC:10848)
Chromosomal Locus
7q36.3
Encoded Product
SHH — the 19-kDa signal domain, palmitoylated and cholesterylated
Primary Pathway
SHH gradient → PTCH relief → SMO → GLI transcription (the morphogen patterning program)
Clinical / Therapeutic Role
Holoprosencephaly (germline); basal-cell carcinoma and SHH-subtype medulloblastoma; vismodegib
Gene Structure & Expression
Genomic organization: Three exons; the self-cleaving C-terminal intein-like domain attaching cholesterol (the only cholesterol-modified animal protein), the N-terminal signal palmitoylated by Hhat — the double lipidation confining SHH's range and requiring the dedicated release machinery.
Expression: Notochord, floor plate, zone of polarizing activity (limb), and the embryonic organizer sites — the morphogen sources the gradients stream from.
Nomenclature note: The video-game naming (1993, the Tabin/McMahon labs) the field's folklore — SHH the best-known of the named morphogens; the formal synonym "motor neuron and kidney pars 6" (MKP6) the dry alternative.
Developmental gradient depth: The neural-tube work (the Jessell/Dessaud concentration-time mapping) the morphogen field's quantitative monument — the ventral progenitor domains as SHH's dose-response curve made flesh; the limb ZPA file its twin.
Morphogen program: The ventral-neural-tube concentration-time integral establishing progenitor domains — the quantitative morphogen model's proof case; the protein page for the PTCH-SMO-GLI cascade.
Cancer arm: Ligand-independent pathway activation (PTCH1 loss in Gorlin syndrome's basal-cell carcinomas, SHH-subtype medulloblastoma) versus ligand-dependent (tumor-stroma) — vismodegib/sonidegib the SMO inhibitors built on the genetics.
Clinical & Therapeutic Significance
Clinical genetics: Germline SHH variants the holoprosencephaly spectrum's commonest single-gene cause; PTCH1 (Gorlin), GLI3 (Pallister-Hall/Greig) the pathway siblings; cyclopamine's Veratrum teratology the pathway's pharmacological origin story.
Therapeutics: Vismodegib/sonidegib in advanced basal-cell carcinoma; the medulloblastoma subtype's targeted programs; smoothened-resistance (SMO mutations) driving the next generation.